{
  "actions": [
    {
      "acted_at": "2015-10-09", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2015-10-16", 
      "in_committee": null, 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr3731-114", 
  "bill_type": "hr", 
  "by_request": false, 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "114", 
  "cosponsors": [
    {
      "district": "17", 
      "name": "Rooney, Thomas J.", 
      "sponsored_at": "2015-10-09", 
      "state": "FL", 
      "thomas_id": "01916", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2015-10-09", 
  "number": "3731", 
  "official_title": "To establish a Rare Disease Therapeutics Corporation to encourage the development of high-risk, high-return therapies for rare diseases, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [], 
  "short_title": "RaD Fund Act", 
  "sponsor": {
    "district": "51", 
    "name": "Vargas, Juan", 
    "state": "CA", 
    "thomas_id": "02112", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2015-10-09", 
  "subjects": [
    "Advisory bodies", 
    "Department of Health and Human Services", 
    "Drug safety, medical device, and laboratory regulation", 
    "Drug therapy", 
    "Health", 
    "Health programs administration and funding", 
    "Health technology, devices, supplies", 
    "Medical research", 
    "National Institutes of Health (NIH)", 
    "Research administration and funding", 
    "Research and development"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2015-10-09", 
    "text": "Rare Disease Fund Act or the RaD Fund Act\n\nThis bill requires the National Institutes of Health (NIH) to organize the Rare Disease Therapeutics Corporation to purchase rights to, fund the development of, and sell ownership interests in drugs, biological products, and medical devices for rare diseases.\n\nThe NIH must sell stock in the corporation to investors as soon as practicable. The corporation and the NIH may enter into an agreement under which the NIH maintains an ownership interest in the corporation in exchange for providing the corporation with intellectual property or other assistance. The corporation is prohibited from paying dividends on its stock.\n\nThe corporation must sell its interest in a rare disease therapy prior to the therapy entering large-scale clinical trials.\n\nThe corporation must issue bonds guaranteed by the United States and may issue bonds backed by the corporation. For purposes of securities laws, the securities of the corporation are not issued or guaranteed by the federal government.\n\nThe bill establishes within the NIH the Rare Disease Therapeutics Corporation Science Advisory Council to advise the corporation on the purchase, sale, and development of rare disease therapies."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "RaD Fund Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Rare Disease Fund Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To establish a Rare Disease Therapeutics Corporation to encourage the development of high-risk, high-return therapies for rare diseases, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2016-06-25T06:54:52-04:00", 
  "url": "http://thomas.loc.gov/cgi-bin/bdquery/z?d114:HR3731:@@@L&summ2=m&"
}